Brief: Bicycle Therapeutics Says Announces Expedited Development Plan For Bt8009 In Metastatic Bladder Cancer
11/09/2023 12:28
Sept 11 (Reuters) - Bicycle Therapeutics PLC BCYC.O :
* BICYCLE THERAPEUTICS PLC - ANNOUNCES EXPEDITED DEVELOPMENT
PLAN
FOR BT8009 IN METASTATIC BLADDER CANCER
* BICYCLE THERAPEUTICS PLC - ALIGNMENT WITH U.S. FDA ON
DESIGN OF
PHASE 2/3 REGISTRATIONAL TRIAL, TO BE INITIATED IN 1Q 2024
* BICYCLE THERAPEUTICS PLC - DISCUSSIONS WITH FDA ABOUT
DESIGN OF
CONFIRMATORY TRIAL FOR PREVIOUSLY TREATED METASTATIC BLADDER
CANCER ARE ONGOING
Source text for Eikon: ID:nBw46Znzca
Further company coverage: BCYC.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Bicycle Therapeutics
See all newsBicycle Therapeutics Q1 revenue drops after partnership terminations
Brief: Bicycle Therapeutics Announces Oral And Poster Presentations At The Aacr Annual Meeting 2026
UK's Bicycle Therapeutics Q4 revenue jumps, proposes 30% workforce reduction
Brief: Bicycle Therapeutics Says Travis Thompson Appointed As CFO, Succeeds Alethia Young
Bicycle Therapeutics Q3 net loss widens as R&D costs rise